AnaptysBio CMO Trims Stake After Option Exercise as Director Reports Separate Sale

Overview

• Chief Medical Officer Paul F. Lizzul sold 3,650 shares for about $163,191.50, according to a newly reported Form 4 filing.
• Lizzul’s transaction stemmed from exercising 8,525 options, with an immediate sale of part of the shares and a post-trade direct holding of 42,088 shares from 45,738.
• Director J. Anthony Ware executed an open-market sale of 3,900 shares on Dec. 23 for $193,342.50, cutting his direct stake to 9,630 shares from 13,530.
• The filings report only direct holdings for both insiders, with no trusts, derivatives, or indirect entities involved in the sales.
• Coverage places the moves after a roughly 214%–265% one-year stock increase, with recent metrics citing a market cap of about $1.24–$1.39 billion and TTM revenue of $169.47 million.